Search results for "ACTH"

showing 10 items of 21 documents

Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease.

2018

Introduction: Cushing’s disease (CD) is characterized by procoagulative profile. Treatment with cortisol-reducing medications might normalize the coagulation impairment potentially eliminating the risk of thromboembolic complications. Aim: The aim of this prospective study is to evaluate the effectiveness of 6–12 months of treatment with pasireotide (Signifor®, Novartis) 600 µg twice daily on coagulative factors in 21 patients (16 females, mean age 46 ± 12.2 years) with CD. Biochemical, hormonal (urinary free cortisol, UFC; late night salivary cortisol, LNSC; ACTH) and coagulative parameters as Protrombin time (PT), aPTT, factors VIII, IX and XI, antithrombin III, protein C, protein S, fibr…

Cortisol secretionAdultBlood GlucoseMalemedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismGastroenterologySettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicinemedicineHumansProspective StudiesProspective cohort studyThromboprophylaxisPituitary ACTH HypersecretionBlood CoagulationClotting factorCoagulationbusiness.industryAnticoagulantCoagulation; Cushing’s disease; Pasireotide; Pituitary; Thromboprophylaxis; Endocrinology Diabetes and Metabolism; EndocrinologyCushing's diseaseCushing’s diseaseMiddle Agedmedicine.diseasePasireotidePasireotideDiabetes and MetabolismCoagulative necrosisTreatment OutcomechemistryPituitary030220 oncology & carcinogenesisConcomitantThromboprophylaxiFemaleBlood Coagulation TestsbusinessSomatostatinEndocrine
researchProduct

Excretion and measurement of corticosterone and testosterone metabolites in bank voles (Myodes glareolus)

2017

The bank vole is a commonly used model species in behavioral and ecophysiological studies. Thus, presenting a validated method for noninvasive monitoring of corticosterone and testosterone secretion is of high relevance. Here, we evaluated the effect of time of day and an ACTH challenge test on measured fecal corticosterone (FCM) and testosterone (FTM) metabolites in both sexes. Furthermore, we performed radiometabolism experiments for both steroids and sexes to study metabolism and excretion of 3H-corticosterone and 3H-testosterone. FCM and FTM were analysed with a 5α-pregnane-3β,11β,21-triol-20-one enzyme immunoassay (EIA) and a testosterone (measuring 17β-hydroxyandrostanes) EIA, respect…

Male0106 biological sciences0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentUrineUrinalysisradiometabolism010603 evolutionary biology01 natural sciencesSteroidImmunoenzyme TechniquesExcretionFeces03 medical and health scienceschemistry.chemical_compoundstressEndocrinologyCorticosteroneInternal medicinemedicineAnimalsTestosteronebank voleta413TestosteroneFecesandrogeenitbiologyArvicolinaeandrogensMetabolismbiology.organism_classificationnon-invasive methodsBank voleACTH challenge030104 developmental biologyEndocrinologychemistryta1181FemaleAnimal Science and ZoologyCorticosterone
researchProduct

Corticotroph aggressive pituitary tumours and carcinomas frequently harbour ATRX mutations

2021

Abstract Context Aggressive pituitary tumors (APTs) are characterized by unusually rapid growth and lack of response to standard treatment. About 1% to 2% develop metastases being classified as pituitary carcinomas (PCs). For unknown reasons, the corticotroph tumors are overrepresented among APTs and PCs. Mutations in the alpha thalassemia/mental retardation syndrome X-linked (ATRX) gene, regulating chromatin remodeling and telomere maintenance, have been implicated in the development of several cancer types, including neuroendocrine tumors. Objective To study ATRX protein expression and mutational status of the ATRX gene in APTs and PCs. Design We investigated ATRX protein expression by us…

Male0301 basic medicineEndocrinology Diabetes and MetabolismClinical Biochemistrypituitary adenomapituitary carcinomaBiochemistryPATHWAYCohort Studies0302 clinical medicineEndocrinologyGene FrequencyTELOMERESCorticotrophsClinical Laboratory MedicineGenomicsMiddle AgedCushing’s diseaseEUROPEAN-SOCIETY3. Good healthEuropeKlinisk laboratoriemedicinACTH-Secreting Pituitary Adenoma030220 oncology & carcinogenesisDAXX/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingCushing's diseaseFemaleATRX (alpha thalassemia/mental retardation syndrome X-linked); aggressive PitNETs; pituitary carcinoma; pituitary adenoma; Cushings diseaseAcademicSubjects/MED00250EXPRESSIONAdenomaAdultX-linked Nuclear Proteinmedicine.medical_specialtyGENESAdolescentATRX (alpha thalassemia/mental retardation syndrome X-linked)3122 CancersNonsense mutationContext (language use)CLASSIFICATIONYoung Adult03 medical and health sciencesDeath-associated protein 6SDG 3 - Good Health and Well-beingPituitary adenomaInternal medicineADENOMASmedicineHumansGenetic Predisposition to DiseaseNeoplasm InvasivenessPituitary NeoplasmsClinical Research ArticlesATRXAgedCancer och onkologiaggressive PitNETsbusiness.industryCarcinomaBiochemistry (medical)Pituitary tumorsCancerAMPLIFICATIONNeuroendocrinologymedicine.disease030104 developmental biologyEndocrinologyPituitary3121 General medicine internal medicine and other clinical medicineCancer and OncologyMutationPituitary carcinomaCancer researchbusinessATRX (alpha thalassemia/mental retardation syndrome X-linked); Cushing’s disease; aggressive PitNETs; pituitary adenoma; pituitary carcinoma
researchProduct

Pasireotide treatment reduces cardiometabolic risk in Cushing’s disease patients: an Italian, multicenter study

2018

Purpose: Patients with Cushing’s disease (CD) experience metabolic alterations leading to increased cardiovascular mortality. Recently, the visceral adiposity index (VAI) has been proposed as a marker of visceral adipose tissue dysfunction (ATD) and of the related cardiometabolic risk. We aimed to evaluate the impact of 12-month pasireotide treatment on cardiometabolic risk in CD patients. Methods: This is a multicentre, prospective, and observational study. Sixteen CD patients, referred to the Endocrine Units of the University Hospitals of Messina, Napoli, Padova, and Palermo (Italy), successfully treated with pasireotide for 12 month have been enrolled. In all patients, we assessed anthro…

MaleEndocrinology Diabetes and MetabolismCardiometabolic risk Cushing’s disease hypercortisolism pasireotide visceral adiposity indexLongitudinal StudieDisease030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyRisk FactorsMedicineLongitudinal StudiesProspective StudiesAdiposityFramingham Risk ScoreCushing’s diseaseCushing’s diseaseMiddle AgedPasireotideDiabetes and MetabolismHeart DiseaseItalyAtherosclerosiObesity AbdominalFemaleSomatostatinHumanAdultmedicine.medical_specialtyWaistHeart DiseasesHypercortisolism030209 endocrinology & metabolismIntra-Abdominal Fat03 medical and health sciencesMetabolic DiseasesInternal medicineDiabetes mellitusCardiometabolic risk; Cushing’s disease; Hypercortisolism; Pasireotide; Visceral adiposity index; Endocrinology Diabetes and Metabolism; EndocrinologyHumansPituitary ACTH Hypersecretionbusiness.industryRisk FactorCushing's diseaseAnthropometryAtherosclerosismedicine.diseasePasireotideCardiometabolic riskMetabolic DiseaseVisceral adiposity indexProspective StudiechemistryObservational studybusiness
researchProduct

Pasireotide versus pituitary surgery: a retrospective analysis of 12 months of treatment in patients with Cushing’s disease

2017

Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications

Pituitary glandmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismpasireotide cushing diseaseSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyDiabetes mellitusmedicineIn patientbusiness.industryPituitary ACTH hypersecretionRetrospective cohort studyCushing's diseasemedicine.diseasePasireotideSurgerymedicine.anatomical_structurechemistry030220 oncology & carcinogenesisPituitary surgerybusinessEndocrine
researchProduct

Addison Disease and Atrophic Gastritis: High Persistent ACTH Levels Although an Adequate Treatment

2014

Settore MED/38 - Pediatria Generale E SpecialisticaAddison Disease Atrophic Gastritis ACTH
researchProduct

Vitamin D Deficiency in Cushing’s Disease: Before and After Its Supplementation

2022

Background: The primary objective of the study was to assess serum 25-hydroxyvitamin D [25(OH)D] values in patients with Cushing’s disease (CD), compared to controls. The secondary objective was to assess the response to a load of 150,000 U of cholecalciferol. Methods: In 50 patients with active CD and 48 controls, we evaluated the anthropometric and biochemical parameters, including insulin sensitivity estimation by the homeostatic model of insulin resistance, Matsuda Index and oral disposition index at baseline and in patients with CD also after 6 weeks of cholecalciferol supplementation. Results: At baseline, patients with CD showed a higher frequency of hypovitaminosis deficiency (p = 0…

cholecalciferolhypercortisolism.Nutrition and DieteticsDietary SupplementsHumansPituitary ACTH HypersecretionVitamin D Deficiencyglucocorticoid; hypercortisolism; 25-hydroxyvitamin D; cholecalciferol25-hydroxyvitamin DFood ScienceRicketsNutrients; Volume 14; Issue 5; Pages: 973
researchProduct

Pharmacological Characterization of Melanocortin Receptors in Fish Suggests an Important Role for ACTH

2005

The melanocortin (MC) receptor subtypes have distinctive characteristic binding profiles. We found that the trout and Fugu MC4 receptors have similar affinity for alpha-MSH and beta-MSH and a much higher affinity for ACTH than does the human MC4 receptor. The Fugu MC1 and the trout and Fugu MC5 receptors also have higher affinity for ACTH-derived peptides than alpha-, beta-, or gamma-MSH. It is tempting to speculate that ACTH-derived peptides may have played an important role as "original" ligands at the MC receptors, while the specificity of the different subtypes for the alpha-, beta-, and gamma-MSH peptides may have appeared at later stages during vertebrate evolution.

endocrine systemmedicine.medical_specialtyanimal structuresAlpha (ethology)BiologyGeneral Biochemistry Genetics and Molecular BiologyAdrenocorticotropic HormoneHistory and Philosophy of ScienceInternal medicinemedicineAnimalsHumansACTH receptorReceptorBeta (finance)G protein-coupled receptorintegumentary systemFuguReceptors MelanocortinGeneral NeurosciencefungiFishesMelanocortin 3 receptorCell biologyEndocrinologyMelanocortinhormones hormone substitutes and hormone antagonistsProtein BindingAnnals of the New York Academy of Sciences
researchProduct

The Fundamental Role of Melanocortins in Brain Processes

2003

The discoveries of the latest ten years have shed new light in understanding the roles of melanocortins and their receptors in brain functions and in the development of different pathologies. Since 1992 when genes encoded melanocortin receptor five subtypes were identified, cloned and characterized, the molecular mechanisms underlying different effects such as skin darkening, behaviour, food intake, anti-inflammatory action, analgesia have been clarified. The contribution of melanocortins and their receptors in the physiological control of organism homeostasis has become as the background for the search of agonists and antagonists of separate receptor subtypes, that can be targeted to the m…

integumentary systemdigestive oral and skin physiologyBiologyVentral tegmental areamedicine.anatomical_structureImmune systemMelanocortin receptormedicineACTH receptorMelanocortinReceptorNeuroscienceOrganismMelanocortins
researchProduct

New Melanocortin 1 Receptor Binding Motif Based on the C-Terminal Sequence of ?-Melanocyte-Stimulating Hormone

2006

The C-terminal tripeptide of the alpha-melanocyte stimulating hormone (alpha-MSH11-13) possesses strong antiinflammatory activity without known cellular target. In order to better understand the structural requirements for function of such motif, we designed, synthesized and tested out Trp- and Tyr-containing analogues of the alpha-MSH11-13. Seven alpha-MSH11-13 analogues were synthesized and characterized for their binding to the melanocortin receptors recombinantly expressed in insect (Sf9) cells, infected with baculovirus carrying corresponding MC receptor DNA. We also tested these analogues on B16-F1 mouse melanoma cells endogenously expressing the MC1 receptor for binding and for abili…

medicine.medical_specialtyGrowth-hormone-releasing hormone receptorProtein ConformationAmino Acid MotifsMelanoma ExperimentalBiologyToxicologyBinding CompetitiveMiceThyrotropin-releasing hormone receptorInternal medicineChlorocebus aethiopsmedicineEnzyme-linked receptorAnimalsHumansACTH receptorMelanocyte-Stimulating HormonesReceptorPharmacologyGeneral MedicineMelanocortin 3 receptorCell biologyEndocrinologyCOS CellsEstrogen-related receptor gammaMelanocortinReceptor Melanocortin Type 1Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology
researchProduct